Rapid Exchange Devices Observational Registry. (RXRegistry)
Prospective, Non-randomized, Multicentre, Observational Registry to Assess Clinically Relevant Benefit of Performing the Whole PTA Procedure Using the Rapid Exchange (RX) Devices.
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Forventet)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Aalst, Belgien
- Onze-Lieve-Vrouwziekenhuis (OLV) Aalst
-
Antwerp, Belgien
- GasthuisZusters Antwerpen (GZA) Ziekenhuizen
-
Auvelais-Val de Sambre, Belgien
- Centre Hospitalier Régional (CHR) du Val de Sambre
-
Hasselt, Belgien
- Jessa Ziekenhuis
-
Liège, Belgien
- Centre Hospitalier Universitaire (CHU) Liège
-
-
-
-
-
Burgos, Spanien
- Hospital Universitario de Burgos
-
Girona, Spanien
- Hospital Universitari Dr. Josep Trueta de Girona
-
Santander, Spanien
- Hospital Universitario Marqués de Valdecilla
-
Valladolid, Spanien
- Hospital Clínico Universitario de Valladolid
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients with symptomatic one or two legs ischemia, requiring treatment of SFA or popliteal artery
- Rutherford classification 2-5
- Single lesion with recoiling/dissection/restenosis after balloon angioplasty or de novo lesions with stenosis or occlusion,
- Target vessel reference diameter ≥4mm and ≤7mm (by visual estimate)
- At least one patent (less than 50% stenosis) tibioperoneal run-off vessel confirmed by baseline angiography
- Patient is suitable candidate for femoral-popliteal artery bypass surgery
Exclusion Criteria:
- Female of child-bearing potential.
- Previous bypass surgery
- In stent restenosis as a target lesion
- Scheduled staged procedure of multiple lesions within the ipsilateral iliac or popliteal arteries within 30 days after index procedure.
- Co-existing aneurysmal disease of the abdominal aorta, iliac or popliteal arteries
- Acute thrombophlebitis or deep venous thrombosis
- Hemodynamic instability
- Untreated inflow disease of the ipsilateral pelvic arteries (more than 50 percent stenosis or occlusion),
- Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy
- Known intolerance to study medications, contrast agents or nitinol.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Safety: composite of all-cause death, amputation, TVR, stroke or bleeding (BARC ≥ 3) up to 1 month
Tidsramme: From start up to 30 Days post procedure.
|
From start up to 30 Days post procedure.
|
|
Total contrast media volume given during the procedure.
Tidsramme: During procedure
|
During procedure
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Total duration of the procedure
Tidsramme: During procedure
|
During procedure
|
|
Total fluoroscopy time
Tidsramme: During procedure
|
During procedure
|
|
Total radiation dose given
Tidsramme: During procedure
|
During procedure
|
|
Technical success defined as a successful access and balloon angioplasty followed by stent placement with achieved recanalization determined by less than 30% residual stenosis by angiography at the baseline procedure.
Tidsramme: Pre- and post-procedure
|
Pre- and post-procedure
|
|
Clinical success defined as technically successful procedure without the events considered in safety composite endpoint (all-cause death, amputation, TVR, stroke or bleeding (BARC ≥ 3) up to 1 month.
Tidsramme: During procedure
|
During procedure
|
|
Total acute complication rate defined as any device- or procedure- related complication up to 1 month post procedure.
Tidsramme: Up to 30 Days post procedure
|
Up to 30 Days post procedure
|
|
Total acute device related complication rate defined as any device complication up to 1 month post procedure.
Tidsramme: Up to 30 Days post procedure
|
Up to 30 Days post procedure
|
|
Ankle-Brachial Index (ABI) improvement at 30 days.
Tidsramme: 30 Days post procedure
|
30 Days post procedure
|
|
Improvement of the Rutherford index at 30 days.
Tidsramme: 30Days post procedure
|
30Days post procedure
|
|
Walking distance at 30 days compared with walking distance before procedure.
Tidsramme: 30 Days post procedure
|
30 Days post procedure
|
|
Bleeding complication as per BARC definitions.
Tidsramme: Up to 30 days post procedure
|
Up to 30 days post procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Christophe Martinez, Centre Hospitalier Universitaire (CHU) Liège
- Ledende efterforsker: Omar Andrés Navarro, Hospital Universitari Dr. Josep Trueta de Girona
- Ledende efterforsker: Josua Van den Berg, Ospedale Regionale di Lugano
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Forventet)
Primær færdiggørelse
Studieafslutning (Forventet)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- T122E2
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .